This past week saw some action on COVID-19 vaccine front, possibly offering more tools to fight the pandemic in next few months.
Dr Reddy’s said it is planning to apply for emergency-use approval (EUA) of Russia's Sputnik V COVID-19 vaccine by March, expects possible approval by the end of that month. The company has contract with Russian sovereign fund RDIF for 125 million patient doses (250 million doses) for India. RDIF has earlier announced that its vaccine would be priced below $10.
The data from clinical trials of Johnson & Johnson and Novavax, which were announced this week, were also positive increasing the chances of the vaccine availability. Interestingly, both these vaccines will be manufactured in India.
India has already rolled out Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin. The government plans to vaccinate 3 crore healthcare and frontline workers in the initial phase of the COVID-19 vaccination. India would need 2.6 billion doses to vaccinate its entire population.